Corporate & Foundation Funders
Thanks to the following organizations for their generous support. Corporate and foundation funders help defer costs associated with ICA programs and services such as advocacy initiatives, awareness raising activities, website support (www.ichelp.org), publication and resource materials development and dissemination, and more. As a 501(C) 3 nonprofit organization, the ICA controls the planning, content, objectives, methods, and execution of all initiatives and projects. The ICA also does not accept advertisement dollars.
 |
is the distributor of Elmiron, the first and only oral medication FDA-approved specifically for the treatment of interstitial cystitis.
www.orthoelmiron.com/orthoelmiron/ |
 |
is the US philanthropic division of Astellas Pharma, Inc. of Japan. Astellas was formed by the merger of Japan's third and fifth largest pharmaceutical companies - Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. With an unrelenting commitment to R&D as a value-creating core of its business, Astellas is consolidated around complementary strengths from Yamanouchi and Fujisawa.
http://www.astellas.com/ |
 |
is the philanthropic organization of Medtronic, Inc. The Medtronic Foundation supports a variety of Programs and Services for non-profit organizations aimed at empowering people with chronic disease.
www.medtronic.com/foundation |
 |
is the maker of InterStim Therapy, an implantable sacral nerve stimulation device for the treatment of urgency frequency, urge incontinence, and retention.
http://www.medtronic.com/ and http://www.interstim.com/ |
 |
makes Prelief, a dietary supplement containing calcium glycerophosphate, which has been shown to help reduce bladder pain and urinary urgency when used with acidic foods and beverages.
http://www.prelief.com/
800-994-4711 |
 |
the maker of CystoProtek, a patent-protected natural oral dietary supplement in softgel capsule form. CystoProtek has been clinically demonstrated to relieve symptoms associated with interstitial cystitis.
http://www.cysto-protek.com/
888-317-0001 |
 |
provides special over-the-counter aloe vera formulas specifically designed to target the symptoms of interstitial cystitis.
http://www.desertharvest.com/ [ Free Samples Available ] |
 |
is a global medical device company that develops, manufactures, and markets products for the minimally invasive treatment of voiding dysfunctions and pelvic disorders including urinary incontinence and overactive bladder symptoms.
http://www.uroplasty.com/ |
 |
the maker of the LoFric hydrophilic catheters and kits for intermittent catheterization. LoFric is the only catheter in the world proven to reduce the risk of both UTIs and long-term complications. 100% latex-free.
http://www.lofric.com/ |
 |
has developed patent-pending, clinically-proven formulas specifically designed for IC/PBS patients and CP/CPPS patients. Cysta-Q targets the urinary frequency, urgency, and pain of IC and is the only clinically proven over-the-counter supplement to be published in peer reviewed medical trade journals such as Techniques in Urology.
http://www.farrlabs.com/
877-284-3976 |
We are making great strides thanks in part to the generous support from our corporate and foundation sponsors. Click on the links above to learn more about these sponsors and their products. Please recognize that many of these are commercial sites and may contain promotional material not necessarily endorsed by the ICA. The efforts of corporate and foundation sponsors help make positive changes in the lives of people with IC:
- Sponsors contribute to many of the vital programs and services offered by the ICA — programs and services that make a difference by reaching out to IC patients, healthcare providers, and researchers
- Private-public partnerships allow us to deliver quality education, support, and advocacy services to people with IC, caregivers, healthcare professionals, and researchers worldwide.
- Corporate donations further the search for better treatment options and, ultimately, a cure for interstitial cystitis.
Revised: November 13, 2008